Experimental drug combo takes on recurrent glioblastoma

NCT ID NCT06410248

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests two drugs—triapine and temozolomide—together in people whose glioblastoma has returned. The goal is to find the safest dose and see how well patients tolerate the combination. About 30 adults with recurrent grade 2-4 glioma will take part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

triapine and temozolomide

What this could lead to

If this works, it could point toward a new combination treatment for recurrent glioblastoma, a brain cancer with few options.

What could go wrong

This is a very early phase 1 trial with only 30 people. The main goal is safety and dosing, not yet proof of effectiveness. Side effects could be significant.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT GLIOBLASTOMA, IDH-WILDTYPE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma grade II glioma grade III glioma IDH-wildtype glioblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Northwestern University

    RECRUITING

    Chicago, Illinois, 60611, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact